Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Tomaschitz

Showing results (101-110 of 123) with videos related to

Pageof 13
Sort By:
Scientific Reports|May 19, 2017
Involvement Of Vascular Aldosterone Synthase In Phosphate-Induced Osteogenic Transformation Of Vascular Smooth Muscle CellsIoana Alesutan, Jakob Voelkl, Martina Feger, et al.
European Journal of Nutrition|April 1, 2018
Effects of vitamin D supplementation on FGF23: a randomized-controlled trialChristian Trummer, Verena Schwetz, Marlene Pandis, et al.
Journal of the American Society of Nephrology : JASN|January 9, 2015
Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D StudiesChristiane Drechsler, Graciela Delgado, Christoph Wanner, et al.
Journal of Hypertension|July 6, 2016
Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trialNicolas Verheyen, Astrid Fahrleitner-Pammer, Burkert Pieske, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|October 13, 2015
Plasma Parathyroid Hormone Is Independently Related to Nocturnal Blood Pressure in Hypertensive Patients: The Styrian Hypertension StudyNicolas D Verheyen, Katharina Kienreich, Martin Gaksch, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|August 24, 2017
Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism: The EPATH trialJulia Wetzel, Stefan Pilz, Martin R Grübler, et al.
Plos One|April 14, 2017
Relationship between bone turnover and left ventricular function in primary hyperparathyroidism: The EPATH trialNicolas Verheyen, Astrid Fahrleitner-Pammer, Evgeny Belyavskiy, et al.
Clinical Chemistry and Laboratory Medicine|April 23, 2017
Low-grade inflammation and tryptophan-kynurenine pathway activation are associated with adverse cardiac remodeling in primary hyperparathyroidism: the EPATH trialNicolas Verheyen, Andreas Meinitzer, Martin Robert Grübler, et al.
Hypertension (Dallas, Tex. : 1979)|March 25, 2015
Effects of vitamin D on blood pressure and cardiovascular risk factors: a randomized controlled trialStefan Pilz, Martin Gaksch, Katharina Kienreich, et al.
ESC Heart Failure|March 7, 2024
Prevalence and prognostic impact of bone disease in chronic heart failure with reduced ejection fractionNicolas Verheyen, Johannes Schmid, Ewald Kolesnik, et al.
Pageof 13

Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
Scientific Reports|May 19, 2017
Involvement Of Vascular Aldosterone Synthase In Phosphate-Induced Osteogenic Transformation Of Vascular Smooth Muscle CellsIoana Alesutan, Jakob Voelkl, Martina Feger, et al.
European Journal of Nutrition|April 1, 2018
Effects of vitamin D supplementation on FGF23: a randomized-controlled trialChristian Trummer, Verena Schwetz, Marlene Pandis, et al.
Journal of the American Society of Nephrology : JASN|January 9, 2015
Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D StudiesChristiane Drechsler, Graciela Delgado, Christoph Wanner, et al.
Journal of Hypertension|July 6, 2016
Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trialNicolas Verheyen, Astrid Fahrleitner-Pammer, Burkert Pieske, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|October 13, 2015
Plasma Parathyroid Hormone Is Independently Related to Nocturnal Blood Pressure in Hypertensive Patients: The Styrian Hypertension StudyNicolas D Verheyen, Katharina Kienreich, Martin Gaksch, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|August 24, 2017
Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism: The EPATH trialJulia Wetzel, Stefan Pilz, Martin R Grübler, et al.
Plos One|April 14, 2017
Relationship between bone turnover and left ventricular function in primary hyperparathyroidism: The EPATH trialNicolas Verheyen, Astrid Fahrleitner-Pammer, Evgeny Belyavskiy, et al.
Clinical Chemistry and Laboratory Medicine|April 23, 2017
Low-grade inflammation and tryptophan-kynurenine pathway activation are associated with adverse cardiac remodeling in primary hyperparathyroidism: the EPATH trialNicolas Verheyen, Andreas Meinitzer, Martin Robert Grübler, et al.
Hypertension (Dallas, Tex. : 1979)|March 25, 2015
Effects of vitamin D on blood pressure and cardiovascular risk factors: a randomized controlled trialStefan Pilz, Martin Gaksch, Katharina Kienreich, et al.
ESC Heart Failure|March 7, 2024
Prevalence and prognostic impact of bone disease in chronic heart failure with reduced ejection fractionNicolas Verheyen, Johannes Schmid, Ewald Kolesnik, et al.
Pageof 13